Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants

Next Previous
X
Search
Trial Profile

A Phase 1, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Sep 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lirentelimab (Primary)
  • Indications Eosinophilic gastroenteritis; Systemic mastocytosis
  • Focus Adverse reactions
  • Sponsors Allakos

    • Most Recent Events

    • 05 Mar 2018 Results assessing pharmacodynamics and safety presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 05 Mar 2018 Results published in the Allakos Media Release
    • 05 Mar 2018 According to Allakos media release, positive results from this trial will be presented at the Joint Congress of the American Academy of Allergy Asthma and Immunology (AAAAI) and the World Allergy Organization (WAO).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top